Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy

Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy

Despite the significant clinical advances with the use of immune checkpoint inhibitors (ICIs) in a wide range of cancer patients, response rates to the therapy are variable and do not always result in long-term tumor regression. The development of ICI-resistant disease is one of the pressing issue i...

Full description

Bibliographic Details
Main Authors: Silvia D’Amico, Patrizia Tempora, Ombretta Melaiu, Valeria Lucarini, Loredana Cifaldi, Franco Locatelli, Doriana Fruci
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Immunology
Subjects:
immunopeptidome
tumor antigens
antigen processing
HLA class I
immune checkpoint inhibitors
TEIPPs
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.948297/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.948297/full

Similar Items